AngioDynamics, Inc. (ANGO)
AngioDynamics, Inc. (ANGO) is a global medical device company specializing in minimally invasive, procedure-driven products for the diagnosis and treatment of vascular and cancerous conditions. Founded in 1988 and headquartered in imaging and therapeutic devices for oncology, vascular access, and peripheral vascular disease, AngioDynamics offers solutions designed to improve patient outcomes and procedural efficiency.
Company News
AngioDynamics reported Q1 fiscal 2026 results with mixed performance, beating adjusted earnings expectations but showing ongoing challenges in profitability. The company saw 12% overall sales growth, driven by med tech segment, but remains years away from consistent profitability.
Insiders have been making significant purchases in Eton Pharmaceuticals, AngioDynamics, and Tile Shop Holdings, indicating their confidence in these companies' prospects.
AngioDynamics (ANGO) has seen a 15.9% decline in the past four weeks, but its oversold RSI and improved earnings estimates suggest a potential turnaround may be on the horizon.
The U.S. autoimmune disease diagnostics market is expected to reach $3.01 billion by 2030, driven by the rising incidence of autoimmune diseases and advancements in diagnostic technologies. Localized autoimmune disease diagnostics and antinuclear antibody tests are expected to dominate the market.
AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
